Therapeutics targeting innate immune/inflammatory responses through the interleukin-6/JAK/STAT signal transduction pathway in patients with cancer

Translational Research

Volumn 167, Issue 1, 2016, Pages 61-66

  Roxburgh, Campbell S D ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CAPECITABINE; COLONY STIMULATING FACTOR 1; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; JANUS KINASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PACRITINIB; PENTRAXIN; RUXOLITINIB; SILTUXIMAB; STAT PROTEIN; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; IL6 PROTEIN, HUMAN;

ADVANCED CANCER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; INFLAMMATION; INNATE IMMUNITY; KIDNEY CANCER; MYELOFIBROSIS; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS;

ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-6; JANUS KINASES; NEOPLASMS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84952066677     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.08.013     Document Type: Review

References (60)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
3. S.S. McAllister, and R.A. Weinberg The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis Nat Cell Biol 16 2014 717 727
4. C.S. Roxburgh, and D.C. McMillan Cancer immunity and inflammation Kerr The Oxford Textbook of Oncology 3rd ed 2015 Oxford University Press ISBN: 9780199656103, In press
5. T. Kottke, N. Boisgerault, R.M. Diaz, and et al. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence Nat Med 19 2013 1625 1631
6. J. Lu, L.L. Marnell, K.D. Marjon, C. Mold, T.W. Du Clos, and P.D. Sun Structural recognition and functional activation of FcgammaR by innate pentraxins Nature 456 2008 989 992
7. A. Peisajovich, L. Marnell, C. Mold, and T.W. Du Clos C-reactive protein at the interface between innate immunity and inflammation Expert Rev Clin Immunol 4 2008 379 390
8. H.L. Rao, J.W. Chen, M. Li, and et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis PLoS One 7 2012 e30806
9. C.S. Roxburgh, and D.C. McMillan The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer Cancer Treat Rev 38 2012 451 466
10. Y. Wu, Q. Zhao, C. Peng, L. Sun, X.F. Li, and D.M. Kuang Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop J Pathol 225 2011 438 447
11. M.J. Proctor, P.G. Horgan, D. Talwar, C.D. Fletcher, D.S. Morrison, and D.C. McMillan Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study Cancer 119 2013 2325 2332
12. C.S. Roxburgh, and D.C. McMillan Role of systemic inflammatory response in predicting survival in patients with primary operable cancer Future Oncol 6 2010 149 163
13. B. Elsberger, L. Lankston, D.C. McMillan, M.A. Underwood, and J. Edwards Presence of tumoural C-reactive protein correlates with progressive prostate cancer Prostate Cancer Prostatic Dis 14 2011 122 128
14. J. Galon, A. Costes, F. Sanchez-Cabo, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
15. J. Galon, W.H. Fridman, and F. Pagès The adaptive immunologic microenvironment in colorectal cancer: a novel perspective Cancer Res 67 2007 1883 1886
16. C.H. Richards, C.S. Roxburgh, A.G. Powell, A.K. Foulis, P.G. Horgan, and D.C. McMillan The clinical utility of the local inflammatory response in colorectal cancer Eur J Cancer 50 2014 309 319
17. J.H. Park, C.S. Roxburgh, and D.C. McMillan Comment on 'Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis' Br J Cancer 111 2014 2372
18. C.I. Diakos, K.A. Charles, D.C. McMillan, and S.J. Clarke Cancer-related inflammation and treatment effectiveness Lancet Oncol 15 2014 e493 e503
19. V.A. Zavala, and A.M. Kalergis New clinical advances in immunotherapy for the treatment of solid tumours Immunology 145 2015 182 201
20. M.R. Galdiero, E. Bonavita, I. Barajon, C. Garlanda, A. Mantovani, and S. Jaillon Tumor associated macrophages and neutrophils in cancer Immunobiology 218 2013 1402 1410
21. N.A. Giraldo, E. Becht, R. Remark, D. Damotte, C. Sautès-Fridman, and W.H. Fridman The immune contexture of primary and metastatic human tumours Curr Opin Immunol 27 2014 8 15
22. T. Kitamura, B.Z. Qian, and J.W. Pollard Immune cell promotion of metastasis Nat Rev Immunol 15 2015 73 86
23. B. Ruffell, and L.M. Coussens Macrophages and therapeutic resistance in cancer Cancer Cell 27 2015 462 472
24. G. Bindea, B. Mlecnik, M. Tosolini, and et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer Immunity 39 2013 782 795
25. S.K. Biswas, and A. Mantovani Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat Immunol 11 2010 889 896
26. J.H. Park, C.H. Richards, D.C. McMillan, P.G. Horgan, and C.S. Roxburgh The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer Ann Oncol 25 2014 644 651
27. J. Medina-Echeverz, F. Aranda, and P. Berraondo Myeloid-derived cells are key targets of tumor immunotherapy Oncoimmunology 3 2014 e28398
28. P. Salama, and C. Platell Host response to colorectal cancer ANZ J Surg 78 2008 745 753
29. E.F. Leitch, M. Chakrabarti, J.E. Crozier, and et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer Br J Cancer 97 2007 1266 1270
30. D.G. Watt, P.G. Horgan, and D.C. McMillan Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review Surgery 157 2015 362 380
31. H. Nozawa, C. Chiu, and D. Hanahan Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis Proc Natl Acad Sci U S A 103 2006 12493 12498
32. G.J. Guthrie, K.A. Charles, C.S. Roxburgh, P.G. Horgan, D.C. McMillan, and S.J. Clarke The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer Crit Rev Oncol Hematol 88 2013 218 230
33. D.C. McMillan The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer Cancer Treat Rev 39 2013 534 540
34. G.J. Guthrie, C.S. Roxburgh, C.H. Richards, P.G. Horgan, and D.C. McMillan Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer Br J Cancer 109 2013 131 137
35. K. Taniguchi, and M. Karin IL-6 and related cytokines as the critical lynchpins between inflammation and cancer Semin Immunol 26 2014 54 74
36. S. Thomas, K.H. Fisher, J.A. Snowden, S.J. Danson, S. Brown, and M.P. Zeidler Methotrexate is a JAK/STAT pathway inhibitor PLoS One 10 2015 e0130078
37. S.J. Thomas, J.A. Snowden, M.P. Zeidler, and S.J. Danson The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours Br J Cancer 113 2015 365 371
38. J.J. O'Shea, and R. Plenge JAK and STAT signaling molecules in immunoregulation and immune-mediated disease Immunity 36 2012 542 550
39. M. Chasen, R. Bhargava, and S. Hirschman Immunomodulatory agents for the treatment of cachexia Curr Opin Support Palliat Care 8 2014 328 333
40. C. Montón, S. Ewig, A. Torres, and et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study Eur Respir J 14 1999 218 220
41. B.T. Kaymaz, N. Selvi, G. Saydam, F. Sahin, and B. Kosova Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells Hematology 17 2012 93 99
42. A. Macciò, C. Madeddu, G. Gramignano, and et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life Gynecol Oncol 124 2012 417 425
43. T.S. Solheim, K.C. Fearon, D. Blum, and S. Kaasa Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review Acta Oncol 52 2013 6 17
44. M.L. Slattery, A. Lundgreen, S.A. Kadlubar, K.L. Bondurant, and R.K. Wolff JAK/STAT/SOCS-signaling pathway and colon and rectal cancer Mol Carcinog 52 2013 155 166
45. N.R. Jana NSAIDs and apoptosis Cell Mol Life Sci 65 2008 1295 1301
46. Y. Tian, Y. Ye, W. Gao, and et al. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway Int J Colorectal Dis 26 2011 13 22
47. M. Hussain, A. Javeed, M. Ashraf, N. Al-Zaubai, A. Stewart, and M.M. Mukhtar Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy Pharmacol Res 66 2012 7 18
48. C. Arnaud, F. Burger, S. Steffens, and et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins Arterioscler Thromb Vasc Biol 25 2005 1231 1236
49. M. Chello, G. Patti, D. Candura, and et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery Crit Care Med 34 2006 660 667
50. J.W. Clendening, and L.Z. Penn Targeting tumor cell metabolism with statins Oncogene 31 2012 4967 4978
51. Z. Fang, Y. Tang, J. Fang, and et al. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway PLoS One 8 2013 e62823
52. E.M. Ruderman The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis Bull Hosp Jt Dis (2013) 71 Suppl 1 2013 S29 S32
53. J.F. Rossi, Z.Y. Lu, M. Jourdan, and B. Klein Interleukin-6 as a therapeutic target Clin Cancer Res 21 2015 1248 1257
54. C. Casper, S. Chaturvedi, N.C. Munshi, and et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with Multicentric Castleman disease Clin Cancer Res 21 19 2015 4294 4304
55. R. Chen, and B. Chen Siltuximab (CNTO 328): a promising option for human malignancies Drug Des Devel Ther 9 2015 3455 3458
56. Y. Uchiyama, K. Yorozu, M. Hashizume, Y. Moriya, and M. Mihara Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis Biol Pharm Bull 31 2008 1159 1163
57. K. Ando, F. Takahashi, M. Kato, and et al. Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer PLoS One 9 2014 e102436
58. M.R. Pawlus, L. Wang, and C.J. Hu STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells Oncogene 33 2014 1670 1679
59. C. Harrison, J.J. Kiladjian, H.K. Al-Ali, and et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
60. H.I. Hurwitz, N. Uppal, S.A. Wagner, and et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed J Clin Oncol 2015 [Epub ahead of print]